Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases

Janna Berg

Status

Active, not recruiting

Conditions

Metastases

Primary Tumor

Lung Cancer

Treatments

Genetic: Genome analysis of tissue samples.

Study type

Interventional

Funder types

Other

Identifiers

NCT02301858

SIV 9743

Details and patient eligibility

About

The project aims to compare the histopathological and molecular characteristics of tumour tissue from metastases with similar analyses of the primary tumour in the lung, where it is available.

The investigators will therefore perform analysis of blood samples if possible, to identify predictive markers in blood samples.

Full description

The investigators want to make genome analysis of tissue samples. This involves analysing the RNA, DNA methylation, for example in cancer cells. This will provide information regarding somatic changes in cancer cells, such as mutations. All of the investigators analysis will be cancer-focused, with the goal of increasing understanding of the heterogeneity.

The investigators will therefore perform analysis of blood samples if possible, to identify predictive markers in blood samples. This will then be the miRNA, RNA expression or protein expression in blood samples.

Enrollment

100 estimated patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with metastasizing lung cancer where further treatment is still applicable.

Exclusion criteria

Terminal patients or patients in a reduced general condition with EGOC 3-4, i.e. patients who are confined to bed more than 50% of the day, with no clinical indication to perform sampling of the tumor and metastases.
Patients where further cancer treatment is no longer applicable.
Patients with cognitive impairment.
Patients with inaccessible metastases where sampling may cause distress to the patient and are at increased risk of complications.